3α,24-dihydroxyolean-12-en-28-oic acid | 125137-39-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 3α,24-dihydroxyolean-12-en-28-oic acid
• 英文别名: 3β,23-dihydroxy-12-oleanan-28-oic acid；hederagenin；Hederagenin；(4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
• CAS: 125137-39-5
• 化学式: C₃₀H₄₈O₄
• 分子量: 472.709
• InChiKey: PGOYMURMZNDHNS-PKBNBBQQSA-N

物化性质

• 沸点：
  589.4±50.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  34
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Methods and compositions for treatment of COPD diseases
  申请人：Shanghai KE Pharmaceutical Co., LTD

  公开号：US10786521B2

  公开（公告）日：2020-09-29

  The present disclosure relates to treatment of a pulmonary disease. The methods and kits provided herein facilitate relieving the symptoms resulting from the pulmonary disease (e.g., asthma, chronic obstructive pulmonary disease (COPD), etc.).

  本公开涉及肺部疾病的治疗。本文提供的方法和试剂盒有助于缓解肺部疾病（如哮喘、慢性阻塞性肺病（COPD）等）引起的症状。
• METHODS AND COMPOSITIONS FOR TREATMENT OF COPD DISEASES
  申请人：Shanghai KE Pharmaceutical Co., Ltd

  公开号：EP3131556A1

  公开（公告）日：2017-02-22
• KUDINOSIDES FOR USE IN THE TREATMENT OF COPD DISEASES
  申请人：Shanghai KE Pharmaceutical Co., Ltd

  公开号：EP3131556B1

  公开（公告）日：2019-10-09
• Methods and Compositions for Treatment of COPD Diseases
  申请人：Shanghai KE Pharmaceutical Co., LTD

  公开号：US20180311265A1

  公开（公告）日：2018-11-01

  The present disclosure relates to treatment of a pulmonary disease. The methods and kits provided herein facilitate relieving the symptoms resulting from the pulmonary disease (e.g., asthma, chronic obstructive pulmonary disease (COPD), etc.).
• [EN] METHODS AND COMPOSITIONS FOR TREATMENT OF COPD DISEASES<br/>[FR] MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES LIÉES À LA BPCO
  申请人：NANJING MUCYTE BIOTECHNOLOGY CO LTD

  公开号：WO2015158216A1

  公开（公告）日：2015-10-22

  Disclosed is the use of Kudinosides for the manufacture of treating pulmonary disease. And kits provided herein facilitate relieving the symptoms resulting from the pulmonary disease (e.g., asthma, chronic obstructive pulmonary disease (COPD), etc. ).